| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Haloperidol, a D2 dopamine receptor antagonist, indirectly diminishes GPR153 activity by modulating downstream dopaminergic signaling pathways, which could interfere with GPR153's role in neuromodulation. | ||||||
SCH 23390 | 125941-87-9 | sc-200408 sc-200408A | 5 mg 25 mg | $175.00 $719.00 | 2 | |
SCH 23390 is a selective D1 dopamine receptor antagonist that may reduce GPR153 functional activity by altering the balance of dopamine signaling, potentially affecting pathways that GPR153 is associated with. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a beta-adrenergic receptor antagonist, may lead to the inhibition of GPR153 by attenuating the adrenergic pathways that could overlap with GPR153's regulatory functions in the central nervous system. | ||||||
Ketanserin | 74050-98-9 | sc-279249 | 1 g | $700.00 | ||
Ketanserin, a 5-HT2A serotonin receptor antagonist, can potentially diminish GPR153 activity by modulating serotonergic signaling, a pathway that could crosstalk with GPR153's neuromodulatory actions. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
Ondansetron, a 5-HT3 receptor antagonist, may indirectly inhibit GPR153 activity through the modulation of serotonin pathways that could interact with GPR153 signaling in the central nervous system. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, could lead to decreased GPR153 activity by influencing the adrenergic signaling pathways that may have a regulatory relationship with GPR153. | ||||||
Rimonabant | 168273-06-1 | sc-205491 sc-205491A | 5 mg 10 mg | $72.00 $160.00 | 15 | |
Rimonabant, a CB1 cannabinoid receptor antagonist, may indirectly decrease GPR153 activity by modulating endocannabinoid signaling, which could intersect with signaling pathways involving GPR153. | ||||||
LY 341495 | 201943-63-7 | sc-361244 sc-361244A | 1 mg 10 mg | $87.00 $219.00 | 1 | |
LY 341495, a selective group II (mGlu2/3) metabotropic glutamate receptor antagonist, could diminish GPR153 activity by affecting glutamatergic signaling pathways potentially connected to GPR153. | ||||||
MPEP hydrochloride | 96206-92-7 | sc-279454A sc-279454 | 10 mg 50 mg | $133.00 $510.00 | ||
MPEP, a potent and selective non-competitive mGlu5 receptor antagonist, may indirectly inhibit GPR153 by modulating glutamate signaling, which may crosstalk with GPR153's functional mechanisms. | ||||||
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione, a selective AMPA receptor antagonist, could lead to the inhibition of GPR153 by altering excitatory neurotransmission, which could impact signaling pathways associated with GPR153. | ||||||